Proceeds to support the advancement of Neumora’s mission of building a leading global precision neuroscience company to revolutionize the...

Dose escalation based on positive recommendation from independent data safety monitoring board after safety review of cohort 1 Drug...

Paper reports that Gritstone’s tumor-specific, neoantigen vaccination approach drives priming and boosting of tumor-specific T cells,...

Overall survival (OS) for patients with metastatic, microsatellite stable colorectal cancer (MSS-CRC) who had two prior lines of therapy...

SOMERVILLE, Mass.--(BUSINESS WIRE)--Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known...

Ansa’s next-generation enzymatic DNA synthesis technology will dramatically accelerate innovation across every industry enabled by...

Tomivosertib development strategy updated, including addition of a new cohort in Phase 2b KICKSTART trial in non-small cell lung cancer...

NEW YORK, Jan. 20, 2022 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet...

Amgen wants its future drugs to be multispecific, and so the biopharmaceutical company selected Generate Biomedicines for a $1.9 billion...